drugset / Trial / NCT00580125
Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of this study is demonstrate efficacy and a dose-response in the treatment of acute exacerbation of schizophrenia in comparison to placebo.
Timeline
- Start
- 2007-11
- Primary completion
- 2008-09
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aripiprazole | Other / unclassified | 15 mg | Oral |
| Subject | PF-00217830 | Small molecule | 2 mg | Oral |
| Subject | PF-00217830 | Small molecule | 5 mg | Oral |
| Subject | PF-00217830 | Small molecule | 15 mg | Oral |